PURPOSE: Patients with acute leukemia refractory to induction or reinduction chemotherapy have poor prognoses if they do not undergo hematopoietic stem-cell transplantation (HSCT). However, HSCT when a patient is not in complete remission (CR) is of uncertain benefit. We hypothesized that pretransplantation variables may define subgroups that have a better prognosis. PATIENTS AND METHODS: Overall, 2,255 patients who underwent transplantation for acute leukemia in relapse or with primary induction failure after myeloablative conditioning regimen between 1995 and 2004 were reported to the Center for International Blood and Marrow Transplant Research. The median follow-up of survivors was 61 months. We performed multivariate analysis of pretransplantation variables and developed a predictive scoring system for survival. RESULTS: The 3-year overall survival (OS) rates were 19% for acute myeloid leukemia (AML) and 16% for acute lymphoblastic leukemia (ALL). For AML, five adverse pretransplantation variables significantly influenced survival: first CR duration less than 6 months, circulating blasts, donor other than HLA-identical sibling, Karnofsky or Lansky score less than 90, and poor-risk cytogenetics. For ALL, survival was worse with the following: first refractory or second or greater relapse, > or = 25% marrow blasts, cytomegalovirus-seropositive donor, and age of 10 years or older. Patients with AML who had a predictive score of 0 had 42% OS at 3 years, whereas OS was 6% for a score > or = 3. Patients with ALL who had a score of 0 or 1 had 46% 3-year OS but only 10% OS rate for a score > or = 3. CONCLUSION: Pretransplantation variables delineate subgroups with different outcomes. HSCT during relapse can achieve long-term survival in selected patients with acute leukemia.
PURPOSE:Patients with acute leukemia refractory to induction or reinduction chemotherapy have poor prognoses if they do not undergo hematopoietic stem-cell transplantation (HSCT). However, HSCT when a patient is not in complete remission (CR) is of uncertain benefit. We hypothesized that pretransplantation variables may define subgroups that have a better prognosis. PATIENTS AND METHODS: Overall, 2,255 patients who underwent transplantation for acute leukemia in relapse or with primary induction failure after myeloablative conditioning regimen between 1995 and 2004 were reported to the Center for International Blood and Marrow Transplant Research. The median follow-up of survivors was 61 months. We performed multivariate analysis of pretransplantation variables and developed a predictive scoring system for survival. RESULTS: The 3-year overall survival (OS) rates were 19% for acute myeloid leukemia (AML) and 16% for acute lymphoblastic leukemia (ALL). For AML, five adverse pretransplantation variables significantly influenced survival: first CR duration less than 6 months, circulating blasts, donor other than HLA-identical sibling, Karnofsky or Lansky score less than 90, and poor-risk cytogenetics. For ALL, survival was worse with the following: first refractory or second or greater relapse, > or = 25% marrow blasts, cytomegalovirus-seropositive donor, and age of 10 years or older. Patients with AML who had a predictive score of 0 had 42% OS at 3 years, whereas OS was 6% for a score > or = 3. Patients with ALL who had a score of 0 or 1 had 46% 3-year OS but only 10% OS rate for a score > or = 3. CONCLUSION: Pretransplantation variables delineate subgroups with different outcomes. HSCT during relapse can achieve long-term survival in selected patients with acute leukemia.
Authors: Charles Craddock; Sandeep Nagra; Andrew Peniket; Cassandra Brookes; Laura Buckley; Emmanouil Nikolousis; Nick Duncan; Sudhir Tauro; John Yin; Effie Liakopoulou; Panos Kottaridis; John Snowden; Donald Milligan; Gordon Cook; Eleni Tholouli; Tim Littlewood; Karl Peggs; Paresh Vyas; Fiona Clark; Mark Cook; Stephen Mackinnon; Nigel Russell Journal: Haematologica Date: 2009-11-30 Impact factor: 9.941
Authors: K T Godder; L J Hazlett; S H Abhyankar; K Y Chiang; N P Christiansen; K D Bridges; C G Lee; S S Geier; K S Goon-Johnson; A P Gee; A R Pati; R S Parrish; P J Henslee-Downey Journal: J Clin Oncol Date: 2000-05 Impact factor: 44.544
Authors: M Michallet; X Thomas; J P Vernant; M Kuentz; G Socié; H Espérou-Bourdeau; N Milpied; D Blaise; B Rio; J Reiffers; J P Jouet; J Y Cahn; J H Bourhis; B Lioure; M Leporrier; J J Sotto; G Souillet; L Sutton; P Bordigoni; F Dreyfus; H Tilly; N Gratecos; M Attal; P Y Leprise; F Déméocq; G Michel; A Buzyn; B Delmas-Marsalet; F Bernaudin; N Ifrah; A Sadoun; D Guyotat; M Cavazzana-Cavo; D Caillot; T De Revel; J P Vannier; A Baruchel; N Fegueux; M L Tanguy; A Thiébaut; A Belhabri; E Archimbaud Journal: Bone Marrow Transplant Date: 2000-12 Impact factor: 5.483
Authors: M L Slovak; K J Kopecky; P A Cassileth; D H Harrington; K S Theil; A Mohamed; E Paietta; C L Willman; D R Head; J M Rowe; S J Forman; F R Appelbaum Journal: Blood Date: 2000-12-15 Impact factor: 22.113
Authors: R A Brown; S N Wolff; J W Fay; L Pineiro; R H Collins; J P Lynch; D Stevens; J Greer; R H Herzig; G P Herzig Journal: Blood Date: 1995-03-01 Impact factor: 22.113
Authors: D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas Journal: Bone Marrow Transplant Date: 1995-06 Impact factor: 5.483
Authors: Gerard Michel; Vanderson Rocha; Sylvie Chevret; William Arcese; Kah-Wah Chan; Alexandra Filipovich; Tsuneo A Takahashi; Marcus Vowels; Juan Ortega; Pierre Bordigoni; Peter J Shaw; Isaac Yaniv; Alexandra Machado; Pedro Pimentel; Franca Fagioli; Amparo Verdeguer; Jean Pierre Jouet; Blanca Diez; Euripedes Ferreira; Ricardo Pasquini; Joseph Rosenthal; Eric Sievers; Chiara Messina; Anna Paola Iori; Federico Garnier; Irina Ionescu; Franco Locatelli; Eliane Gluckman Journal: Blood Date: 2003-08-14 Impact factor: 22.113
Authors: E R Nemecek; T A Gooley; A E Woolfrey; P A Carpenter; D C Matthews; J E Sanders Journal: Bone Marrow Transplant Date: 2004-11 Impact factor: 5.483
Authors: J C Biggs; M M Horowitz; R P Gale; R C Ash; K Atkinson; W Helbig; N Jacobsen; G L Phillips; A A Rimm; O Ringdén Journal: Blood Date: 1992-08-15 Impact factor: 22.113
Authors: H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas Journal: Am J Med Date: 1980-08 Impact factor: 4.965
Authors: R Cotugno; R Fortunato; A Santoro; D Gallotta; A Braca; N De Tommasi; M A Belisario Journal: Cell Prolif Date: 2011-12-14 Impact factor: 6.831
Authors: R M Luo; W M Da; X M Zhang; Z L Du; Y J Si; Y Wang; Y Yue; W Chen; B Hu; G S Xing; Z C Feng Journal: Bone Marrow Transplant Date: 2015-11-23 Impact factor: 5.483
Authors: N Kawashima; Y Inamoto; T Sato; M Nakashima; Y Kagaya; K Watakabe; A Seto; N Fukushima; S Kurahashi; Y Ozawa; K Miyamura Journal: Bone Marrow Transplant Date: 2016-02-15 Impact factor: 5.483
Authors: Joan How; Michael Slade; Khoan Vu; John F DiPersio; Peter Westervelt; Geoffrey L Uy; Camille N Abboud; Ravi Vij; Mark A Schroeder; Todd A Fehniger; Rizwan Romee Journal: Biol Blood Marrow Transplant Date: 2017-01-10 Impact factor: 5.742
Authors: Anthony Stein; Joycelynne Palmer; Ni-Chun Tsai; Monzr M Al Malki; Ibrahim Aldoss; Haris Ali; Ahmed Aribi; Len Farol; Chatchada Karanes; Samer Khaled; An Liu; Margaret O'Donnell; Pablo Parker; Anna Pawlowska; Vinod Pullarkat; Eric Radany; Joseph Rosenthal; Firoozeh Sahebi; Amandeep Salhotra; James F Sanchez; Tim Schultheiss; Ricardo Spielberger; Sandra H Thomas; David Snyder; Ryotaro Nakamura; Guido Marcucci; Stephen J Forman; Jeffrey Wong Journal: Biol Blood Marrow Transplant Date: 2017-01-10 Impact factor: 5.742
Authors: K R Schultz; M Devidas; W P Bowman; A Aledo; W B Slayton; H Sather; H W Zheng; S M Davies; P S Gaynon; M Trigg; R Rutledge; D Jorstad; A J Carroll; N Heerema; N Winick; M J Borowitz; S P Hunger; W L Carroll; B Camitta Journal: Leukemia Date: 2014-01-17 Impact factor: 11.528